Patents by Inventor Mark E. Hayes

Mark E. Hayes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240325525
    Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.
    Type: Application
    Filed: May 24, 2024
    Publication date: October 3, 2024
    Applicant: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Alexander Koshkaryev, Ross B. Fulton
  • Publication number: 20240309291
    Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.
    Type: Application
    Filed: May 24, 2024
    Publication date: September 19, 2024
    Applicant: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
  • Patent number: 12077383
    Abstract: A pharmacy system and methodology for individually packaged medications and/or supplements assembled into an order for each patient which can be delivered to a long-term care facility or other institution for patient consumption. The process may include receiving a patient's prescription order, automatically dispensing packaged unit doses, and assembling into individually packaged bags for each patient. Various safeguards and measures built into this system and method increase patient safety, eliminate waste, and increase labor efficiency by reducing and/or minimizing the disposal of unused medications and supplements.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: September 3, 2024
    Assignee: REMEDI TECHNOLOGY HOLDINGS, LLC
    Inventors: Kimberly Hawkes, Steven E. Schneider, Mark Stielau, Richard W Snodgrass, Thomas P. Hayes
  • Patent number: 12077725
    Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.
    Type: Grant
    Filed: December 12, 2022
    Date of Patent: September 3, 2024
    Assignee: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
  • Patent number: 12070471
    Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
    Type: Grant
    Filed: February 17, 2023
    Date of Patent: August 27, 2024
    Assignee: CELATOR PHARMACEUTICALS, INC.
    Inventors: Mark E Hayes, Charles O. Noble, Francis C. Szoka
  • Patent number: 12064479
    Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.
    Type: Grant
    Filed: May 25, 2023
    Date of Patent: August 20, 2024
    Assignee: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Alexander Koshkaryev, Ross B. Fulton
  • Patent number: 12059497
    Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: August 13, 2024
    Assignee: Ipsen Biopharm Ltd.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
  • Publication number: 20230390317
    Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
    Type: Application
    Filed: February 17, 2023
    Publication date: December 7, 2023
    Inventors: Mark E. HAYES, Charles O. NOBEL, Francis C. SZOKA
  • Publication number: 20230381303
    Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.
    Type: Application
    Filed: May 25, 2023
    Publication date: November 30, 2023
    Applicant: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Alexander Koshkaryev, Ross B. Fulton
  • Publication number: 20230126953
    Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.
    Type: Application
    Filed: December 12, 2022
    Publication date: April 27, 2023
    Applicant: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
  • Patent number: 11591544
    Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.
    Type: Grant
    Filed: November 24, 2021
    Date of Patent: February 28, 2023
    Assignee: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
  • Patent number: 11583544
    Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
    Type: Grant
    Filed: December 24, 2019
    Date of Patent: February 21, 2023
    Assignee: CELATOR PHARMACEUTICALS, INC.
    Inventors: Mark E. Hayes, Charles O. Noble, Francis C. Szoka
  • Publication number: 20220411394
    Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.
    Type: Application
    Filed: August 8, 2022
    Publication date: December 29, 2022
    Applicant: Akagera Medicines, Inc.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Alexander Koshkaryev, Ross B. Fulton
  • Publication number: 20220162521
    Abstract: The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.
    Type: Application
    Filed: November 24, 2021
    Publication date: May 26, 2022
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes
  • Publication number: 20210205219
    Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.
    Type: Application
    Filed: March 22, 2021
    Publication date: July 8, 2021
    Applicant: Ipsen Biopharm Ltd.
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark E. Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
  • Publication number: 20210008091
    Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
    Type: Application
    Filed: December 24, 2019
    Publication date: January 14, 2021
    Inventors: Mark E. HAYES, Charles O. NOBLE, Francis C. SZOKA
  • Patent number: 10722467
    Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: July 28, 2020
    Assignee: ZONEONE PHARMA, INC.
    Inventors: Mark E. Hayes, Charles O. Noble, Francis C. Szoka, Jr.
  • Patent number: 10507182
    Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: December 17, 2019
    Assignee: ZONEONE PHARMA, INC.
    Inventors: Mark E. Hayes, Charles O. Noble, Francis C. Szoka, Jr.
  • Publication number: 20190314282
    Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Inventors: Mark E. HAYES, Charles O. NOBLE, Francis C. SZOKA, JR.
  • Publication number: 20190110991
    Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
    Type: Application
    Filed: September 10, 2018
    Publication date: April 18, 2019
    Inventors: Mark E. HAYES, Charles O. NOBLE, Francis C. SZOKA, JR.